The promise of stem cell research, once deemed a scientists' dream, has turned the corner into real marketed products and looks to soon be a multi-billion-dollar industry. Randal Mills, the chief executive officer of Osiris Therapeutics tells the Chicago Tribune's Bruce Japsen about stem cell products already on the market and how more are soon coming to physicians and their patients.
The Promise of Stem Cells Reaching Patients
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Overview
The promise of stem cell research, once deemed a scientists' dream, has turned the corner into real marketed products and looks to soon be a multi-billion-dollar industry. Randal Mills, the chief executive officer of Osiris Therapeutics tells the Chicago Tribune's Bruce Japsen about stem cell products already on the market and how more are soon coming to physicians and their patients.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Phase 3 study results of plozasiran in patients with FCS
FCS and SHTG: Are We Meeting the Need?
IgG4-RD Case Conversations: The Peculiarities of Kidney Involvement
IgG4-RD Case Conversations: Using Thoracic CT as a Diagnostic Clue
IgG4-RD Case Conversations: IgG4-related Autoimmune Pancreatitis and Cholangitis
Digesting IgG4-RD: An Interactive, Multidisciplinary Case Conference
Integrating Guideline Directed Medical Therapy for Patients with CKD and T2D
Level Up Your Skills: Tailoring Management of HF
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?